- Home
- CGEN vs CEE Comparison
CGEN vs CEE Comparison
Compare CGEN & CEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- CEE
- Stock Information
- Founded
- CGEN 1993
- CEE 1990
- Country
- CGEN Israel
- CEE Germany
- Employees
- CGEN N/A
- CEE N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- CEE Finance Companies
- Sector
- CGEN Health Care
- CEE Finance
- Exchange
- CGEN Nasdaq
- CEE Nasdaq
- Market Cap
- CGEN 117.8M
- CEE 101.9M
- IPO Year
- CGEN 2000
- CEE N/A
- Fundamental
- Price
- CGEN $1.47
- CEE $15.63
- Analyst Decision
- CGEN Strong Buy
- CEE
- Analyst Count
- CGEN 1
- CEE 0
- Target Price
- CGEN $4.00
- CEE N/A
- AVG Volume (30 Days)
- CGEN 216.5K
- CEE 22.0K
- Earning Date
- CGEN 05-19-2025
- CEE 01-01-0001
- Dividend Yield
- CGEN N/A
- CEE 3.86%
- EPS Growth
- CGEN N/A
- CEE N/A
- EPS
- CGEN N/A
- CEE N/A
- Revenue
- CGEN $27,589,000.00
- CEE N/A
- Revenue This Year
- CGEN $11.81
- CEE N/A
- Revenue Next Year
- CGEN $28.37
- CEE N/A
- P/E Ratio
- CGEN N/A
- CEE N/A
- Revenue Growth
- CGEN N/A
- CEE N/A
- 52 Week Low
- CGEN $1.13
- CEE $7.80
- 52 Week High
- CGEN $2.66
- CEE $10.32
- Technical
- Relative Strength Index (RSI)
- CGEN 53.98
- CEE 56.23
- Support Level
- CGEN $1.38
- CEE $15.20
- Resistance Level
- CGEN $1.56
- CEE $15.90
- Average True Range (ATR)
- CGEN 0.08
- CEE 0.55
- MACD
- CGEN 0.02
- CEE -0.04
- Stochastic Oscillator
- CGEN 68.97
- CEE 27.91
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.